|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XX40
|
|
gptkbp:brand
|
Aliqopa
|
|
gptkbp:casnumber
|
1207450-98-3
|
|
gptkbp:chemical_formula
|
C22 H24 Cl N5 O3 S
|
|
gptkbp:clinical_trial
|
Phase II
NCT02477696
NCT02379051
NCT02909833
NCT02737766
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:developed_by
|
gptkb:Bayer_AG
|
|
gptkbp:dosage_form
|
60 mg
|
|
gptkbp:drug_interactions
|
anticoagulants
immunosuppressants
antiplatelet agents
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:effective_date
|
2016-09-24
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulation
|
solution for infusion
|
|
gptkbp:frequency
|
once a week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Copanlisib
|
|
gptkbp:indication
|
relapsed follicular lymphoma
|
|
gptkbp:invention
|
patented
2027-09-24
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
PI3 K inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
|
|
gptkbp:research_areas
|
gptkb:immunotherapy
oncology
hematology
targeted therapy
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
gptkb:disease
fatigue
nausea
diarrhea
cardiovascular events
liver enzyme elevation
thrombocytopenia
hyperglycemia
pneumonitis
hypersensitivity reactions
|
|
gptkbp:targets
|
PI3 K pathway
|
|
gptkbp:used_for
|
treatment of follicular lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:bfsLayer
|
6
|